Lifemd, Inc. (LFMD) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Lifemd, Inc. (LFMD) stock forecast summary
Our AI ranks Lifemd, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Lifemd, Inc. is a small-cap company with a market capitalization of $119M. It ranks number 3 by market capitalization among the 5 Services-Offices & Clinics of Doctors of Medicine issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for LFMD is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-13 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, LFMD included.
Follow LFMD freeLFMD price chart and AI forecast
How LFMD ranks among 5379 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Lifemd, Inc. (LFMD) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Offices & Clinics of Doctors of Medicine peers listed below that report each metric.
Valuation & Market
| Metric | LFMD | Rank |
|---|---|---|
| Market Cap | $119M | 3/5 |
| P/B Ratio | 14.94x | – |
| Dividend Yield | 2.61% | – |
| EPS | $0.15 | – |
| Book Value/Share | $0.17 | – |
| Revenue/Share | $3.39 | – |
| FCF/Share | $-0.23 | – |
Profitability & Margins
| Metric | LFMD | Rank |
|---|---|---|
| ROE | -11.4% | 3/6 |
| ROA | -1.5% | 3/8 |
| ROIC | -190.9% | 8/8 |
| Gross Margin | 86.0% | 1/6 |
| Operating Margin | -15.5% | 7/8 |
| Net Margin | -0.6% | 2/8 |
| EBT Margin | -17.0% | 6/8 |
| Tax Rate | 146.7% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | LFMD | Rank |
|---|---|---|
| Current Ratio | 0.90x | 5/8 |
| Quick Ratio | 0.84x | 4/6 |
| D/E Ratio | 6.52x | 3/6 |
| Financial Leverage | 7.52x | 3/6 |
| Interest Coverage | 156.2x | 1/8 |
| Working Capital | -$5M | 4/8 |
Cash Flow
| Metric | LFMD | Rank |
|---|---|---|
| Operating Cash Flow | -$10M | 8/8 |
| Free Cash Flow | -$11M | 6/6 |
| Capital Spending | -$1M | 3/6 |
| OCF Growth YoY | -150.9% | 5/5 |
| FCF Growth YoY | -161.7% | – |
| FCF/Sales | -6.8% | 6/6 |
| CapEx/Sales | 0.7% | 2/6 |
Operational Efficiency
| Metric | LFMD | Rank |
|---|---|---|
| Asset Turnover | 2.73x | 2/7 |
| Receivables Turnover | 14.5x | – |
| Inventory Turnover | 7.7x | – |
| Fixed Assets Turnover | 80.4x | 2/6 |
| Days Sales Outstanding | 25 days | – |
| Days Inventory | 47 days | – |
| Payables Period | 290 days | 1/5 |
| Cash Conversion Cycle | -218 days | – |
Income Statement
| Metric | LFMD | Rank |
|---|---|---|
| Total Revenue | $163M | 5/7 |
| Operating Income | -$25M | 5/8 |
| Net Income | $0.00M | 2/8 |
| SG&A Expense | $149M | 2/7 |
| Cost of Goods Sold | $23M | 5/6 |
Dividend & Shareholder Information
| Metric | LFMD | Rank |
|---|---|---|
| Dividends Per Share | $0.06 | – |
| Payout Ratio | 40.0% | – |
| Shares Outstanding | 48M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $42M | 70.3% of assets |
| Cash & Short-term Investments | $25M | 42.0% of assets |
| Accounts Receivable | $11M | 18.8% of assets |
| Inventory | $3M | 4.9% of assets |
| Total Liabilities | $52M | 86.7% of assets |
| Short-term Debt | $28M | 47.5% of assets |
LFMD quarterly financials and insider trading
Lifemd, Inc. (LFMD) industry peers
Companies classified under the same SEC industry code as Lifemd, Inc. (Services-Offices & Clinics of Doctors of Medicine): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| LFMD Lifemd, Inc. | ▲ | $119M |
| TDOC Teladoc Health, Inc. | ▶ | $1.09B |
| SBC Sbc Medical Group Holdings Inc | ▼ | $554M |
| AIRS Airsculpt Technologies, Inc. | ▲ | $117M |
| HLYK Healthlynked Corp | ▲ | $7M |
| CDIX Cardiff Lexington Corp | ▼ | N/A |
| HIMS Hims & Hers Health, Inc. | ▶ | N/A |
| STLN Starling Oncology, Inc. | ▲ | N/A |
Where LFMD sits on the market map
Lifemd, Inc. (LFMD) stock news
Loading...
Lifemd, Inc. (LFMD) stock forecast FAQ
What is the Lifemd, Inc. (LFMD) stock forecast?
Our AI ranks Lifemd, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Lifemd, Inc. stock predictions?
A per-ticker accuracy statistic for LFMD is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Lifemd, Inc. forecasts updated?
Lifemd, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Lifemd, Inc.'s industry peers?
8 issuers in our coverage, LFMD included, share the SEC industry code Services-Offices & Clinics of Doctors of Medicine. The largest are: Teladoc Health, Inc. (TDOC), Sbc Medical Group Holdings Inc (SBC), Airsculpt Technologies, Inc. (AIRS), Healthlynked Corp (HLYK), Cardiff Lexington Corp (CDIX), Hims & Hers Health, Inc. (HIMS).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.